Bionomics Limited (NASDAQ:BNOX – Get Rating) has been given a consensus rating of "Moderate Buy" by the six analysts that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $16.67.
BNOX has been the subject of a number of recent analyst reports. Evercore ISI reaffirmed an "in-line" rating and issued a $6.00 price objective (down previously from $17.00) on shares of Bionomics in a research report on Tuesday. Loop Capital initiated coverage on Bionomics in a research report on Tuesday, November 1st. They issued a "buy" rating and a $23.00 price objective for the company. Finally, HC Wainwright downgraded Bionomics from a "buy" rating to a "neutral" rating in a research report on Monday.
Get Bionomics alerts:Bionomics Stock Down 16.1 %
Shares of NASDAQ:BNOX opened at $4.94 on Wednesday. Bionomics has a 52 week low of $4.94 and a 52 week high of $13.76. The business has a fifty day simple moving average of $7.62 and a 200-day simple moving average of $7.37.
About Bionomics
(Get Rating)Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.
Featured Articles
- Get a free copy of the StockNews.com research report on Bionomics (BNOX)
- Is There a Prize in Store for Kellogg Shareholders?
- Will AMC's Troubles Affect Its Landlord, EPR Properties?
- General Mills Retreats To More Attractive Territory
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- Can Chewy Fetch Double Digit Gains in 2023?
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.